Results filed 30 October 2026 · Market cap ₹44,541 crore · PE 48.6
GrowthGuidance maintainedTranscript read
Revenue
+57.0%
on a year ago
EBITDA
+65.5%
on a year ago
Profit to shareholders
+81.5%
on a year ago
EBITDA margin
34.2%
+0.1 pts on last quarter
Navin Fluorine reported strong Q2 FY27 results with consolidated revenue advancing 57% YoY to INR 1,191 crores and operating EBITDA margins expanding to 34.2%. Growth was supported by an extension of the Solstice HFO contract through 2032 adding ~USD 180 million, alongside ramping MPP debottlenecking and a 78% YoY surge in CDMO. Key future catalysts include commissioning of the R32 expansion, Chemours liquid cooling plant in Q3 FY27, and Phase II cGMP-4 in Q4 FY27 within an annual capex framework of INR 700-1,000 crores.
Navin Fluorine International Limited, Q2 FY27₹ crore, consolidated
Q2 FY27
Q1 FY27
vs previous quarter
Q2 FY26
vs a year ago
Revenue
1,191
1,045
+13.9%
758
+57.0%
Operating profit (EBIT)
365
315
+15.6%
210
+74.0%
Operating margin
30.6%
30.2%
+45 bps
27.6%
+299 bps
Other income
15.6
35.09
−55.5%
18.21
−14.3%
Exceptional items
0
0
–
0
–
Profit before exceptional items and tax
352
318
+10.4%
198
+78.0%
Profit to shareholders
269
243
+10.7%
148
+81.5%
Share of joint ventures' and associates' profit
−0.01
0
n.m.
0
n.m.
Earnings per share (₹)
52.48
47.45
+10.6%
29.06
+80.6%
Source: Navin Fluorine International Limited’s filing to NSE, 30 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Solstice HFO supply contract extended by 4 years with ~USD 180 million incremental revenue potentialSourceThe tenure of our existing HFO supply contract with Solstice Advanced Materials has been extended by 4 years until December 2032 and will have an additional revenue potential of approximately USD180 million (Transcript page 3-4, Vishad Mafatlal; Presentation page 7)
Strong broad-based quarterly financial performance with consolidated revenue surging 57% YoY and operating EBITDA expanding to 34.2%SourceOperating revenue for the quarter stood at INR1,191 crores, registering a year-on-year growth of 57%. Operating EBITDA grew by 66% year-on-year to INR407 crores, with margins expanding to 34.2% (Transcript page 5-6, Anish Ganatra; Presentation page 5)
CDMO revenue jumped 78% YoY and management reiterated reaching a USD 100 million order book run rateSourceCDMO revenue grew 78% YoY to Rs. 239 Cr (Presentation page 5, 9); 'we are at the striking distance of our USD100 million target in terms of order book visibility' (Transcript page 7, Anish Ganatra)
Guidance
Metric
Guidance
Period
Operating EBITDA MarginSourceFor this year itself, for FY27... we are going to be working on the margins that you see for the first half in the same sort of range for the year... We are not going to change the guidance from 30% [long-term] (Transcript page 12, Anish Ganatra)
Around ~34% for FY27 (in the same range as H1 FY27); maintaining long-term base guidance of 30%
FY27 & Long-term
Annual Capex FrameworkSourceOur capex frame will be in the INR700 crores to INR1,000 crores every year. INR700 crores this year is what we are looking at (Transcript page 11, 13, Anish Ganatra)
INR 700 to INR 1,000 crores annually; FY27 at lower end around INR 700 crores
FY27 and annual frame
Specialty Chemicals Quarterly Run-rateSourceINR350 crores as a run rate, we have said about last 3 quarters... And it will go up because of the reasons we talked before (Transcript page 6, 10, Anish Ganatra)
INR 350 crores base run-rate with further upside from debottlenecking
H2 FY27
CDMO RevenueSourceCDMO, of course, like we said... we are at the striking distance of our USD100 million target in terms of order book visibility (Transcript page 7, Anish Ganatra)
Target of USD 100 million order book visibility by FY27 on track
FY27
Maintained annual capex frame (INR 700-1,000 Cr) and long-term 30% margin threshold, while upgrading FY27 margin expectations to remain near H1 level of ~34%.
Tailwinds
Favorable refrigerant pricing and high merchant volume placement in AHFSourceHPP business grew sequentially and YoY from pricing advantage in ref gases and increased AHF volumes beyond planned captive consumption (Transcript page 6, 12, Anish Ganatra)
Operational efficiency and multi-product mapping in Specialty MPPSourceDebottlenecking of MPP at Dahej commissioned in September 2026; MPP-1 and MPP-2 expected to far exceed PAR (Transcript page 7, 14, Anish Ganatra; Presentation page 8)
Strong CDMO expansion via European major (Fermion) and molecule pipeline maturationSourceIncreasing demand for existing molecules and qualification PO received; two molecules progressing positively including China approval and US FDA fast track (Transcript page 5, 9, 11; Presentation page 9)
Headwinds
Raw material cost inflation across fluorspar, sulfur, and gasSourcePrices for sulfur, gas, and fluorspar have gone up, pressuring gross margins which fell 186 bps YoY on consolidated basis (Transcript page 10, Anish Ganatra; Presentation page 12)
Customer pricing dynamic in extended HFO contract indicates lower annual dollar run rateSourceAnalysts highlighted implied USD 45 million annual run rate for the 4-year USD 180 million extension vs historical ~USD 58-60 million, due to pass-through commercial structuring (Transcript page 8, Sanjesh Jain and Rohit Nagraj)
New businesses and products
partnership · Targeted commissioning in Q3 FY27; POs in hand for delivery in Q4 FY27
Chemours Liquid Cooling Project
Expected benefit
Enable entry into emerging advanced liquid cooling / hypercomputing market
Risks
Technology qualification and adoption timelines across OEM architectures take ~15 months post commissioning
Timeline
Commissioning in Q3 FY27, deliveries start Q4 FY27
Incubating new vertical targeting niche applications in Data Centers, Electronics, Defense & Semiconductors, projected to be 10-15% of business by 2030
The call offered robust detail on project commissioning timelines and pipeline progress across Specialty and CDMO, balanced by firm pushback on commercially sensitive metrics and utilization percentages.
Specific or vague
Management provided clear timelines for capex (R32, Chemours, cGMP4 Phase 2), capital outlay ranges, and target run rates, though remained non-disclosing on utilization rates and Chemours economics under NDA.
Candour
CFO was candid about geopolitical risks, raw material cost inflation (sulfur, gas, fluorspar), and contract structures, though was somewhat defensive on the definition of 'dedicated plants' and exact utilization numbers.
The hard questions
Analysts pressed heavily on the implied run rate drop in the HFO contract extension (USD 45m vs USD 60m), Chemours project delay, and exact plant capacity utilization figures.
What analysts pressed on
Lower revenue run rate on the extended 4-year HFO contract with Solstice compared to historical 7-year run rate
Timeline and commercial qualification risks for Chemours advanced liquid cooling project
Gross margin protection sustainability amidst rising raw material costs (fluorspar, sulfur)
Answers that sidestepped
Refusal to share exact AHF utilization rates: 'So we wouldn't want to talk of utilization rates. I mean, rest assured that we said it's being ramped up' (Transcript page 12, Anish Ganatra)
Bypassing specific economic details or contract margin terms on the HFO pricing beyond high-level potential numbers (Transcript page 16, Anish Ganatra)
Numbers against the story
Management emphasized that gross profit and EBITDA margins were well protected despite high inflation; numbers show consolidated gross margin actually contracted by 186 bps YoY to 56.88% due to higher raw material expenses, but operating leverage in employee and other overheads drove operating EBITDA margin expansion by 176 bps YoY to 34.22%.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.